Search results

  1. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For acute iliofemoral DVT the evidence on efficacy is limited in quality and quantity, therefore this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG651/1 Question Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis

  2. NICE chairman Sharmila Nebhrajani begins her new role

    NICE is delighted to announce that today (26 May 2020) Sharmila Nebhrajani, OBE, has taken up her position as its new chairman following her appointment by the Secretary of State for Health and Social Care and an independent open recruitment process.

  3. NICE publishes new COVID-19 guidelines on cystic fibrosis, chronic obstructive pulmonary disease (COPD) and dermatological conditions treated with drugs affecting the immune response

    NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.

  4. NICE publishes first rapid COVID-19 guidelines

    New guidelines cover the management of patients in critical care, the management of patients who are having kidney dialysis and the management of patients who are receiving systemic anticancer treatments.

  5. NICE to produce rapid COVID-19 guidelines

    NICE has today (20 March 2020) announced that it is developing a series of rapid guidelines with NHS England/Improvement on the active management of patients with suspected and confirmed COVID-19, and in patients without COVID-19, in a number of clinical areas.

  6. The committee noted that there was no clinical evidence showing that having patiromer improved length or quality of life or allowed patients to stay on optimal doses of renin-angiotensin-aldosterone system (RAAS) inhibitors. It therefore considered that it would be valuable to have studies comparing patiromer plus standard care with standard care alone in people with confirmed hyperkalaemia of 6.0 mmol/litre and above, and that these should investigate: - mortality- disease progression- patterns of RAAS inhibitor use- healthcare utilisation and- health-related quality of life. The committee recalled that the DIAMOND trial is ongoing and may help to provide evidence on mortality (see section 3.11). However, the trial is not going to complete until 2022. The committee concluded that the guidance should be reviewed when evidence from DIAMOND is available.

    Recommendation ID TA623/1 Question The committee noted that there was no clinical evidence showing that having patiromer improved length